Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

Neurocognitive (NC) complications continue to afflict a substantial proportion of HIV-infected people taking effective antiretroviral therapy (ART). One contributing mechanism for this is antiretroviral neurotoxicity. Efavirenz (EFV) is associated with short-term central nervous system (CNS) toxicit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neurovirology 2016-04, Vol.22 (2), p.170-178
Hauptverfasser:	Ma, Qing, Vaida, Florin, Wong, Jenna, Sanders, Chelsea A., Kao, Yu-ting, Croteau, David, Clifford, David B., Collier, Ann C., Gelman, Benjamin B., Marra, Christina M., McArthur, Justin C., Morgello, Susan, Simpson, David M., Heaton, Robert K., Grant, Igor, Letendre, Scott L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anti-HIV Agents - therapeutic use Benzoxazines - administration & dosage Benzoxazines - adverse effects Biomedical and Life Sciences Biomedicine CD4 Lymphocyte Count CD4-Positive T-Lymphocytes - drug effects CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - virology Cognitive Dysfunction - complications Cognitive Dysfunction - drug therapy Cognitive Dysfunction - immunology Cognitive Dysfunction - physiopathology Coinfection Drug Therapy, Combination Executive Function - drug effects Female Hepacivirus - physiology Hepatitis C - complications Hepatitis C - drug therapy Hepatitis C - immunology Hepatitis C - physiopathology Hepatitis C virus HIV Infections - complications HIV Infections - drug therapy HIV Infections - immunology HIV Infections - physiopathology HIV-1 - physiology Humans Immunology Infectious Diseases Lentivirus Lopinavir - therapeutic use Male Memory - drug effects Middle Aged Neurology Neuropsychological Tests Neurosciences Retroviridae Ritonavir - therapeutic use Verbal Learning - drug effects Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!